Agrylin (anagrelide HCL)

Company
Roberts Pharmaceutical

Approval Status
Approved December 1998

Treatment for
Cardiology

Possible similar drugs
Agrylin

Areas
Cardiovascular / Cardiology

Agrylin Capsules are indicated for the treatment of patients with Essential Thrombocythemia to reduce the elevated platelet count and the risk of thrombosis.

Agrylin Capsules are also indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.

Agrylin (anagrelide HCL) Drug Information

The Agrylin (anagrelide HCL) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top